Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia-Reference-Cited by-同舟云学术

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia

Published:2018-04-11 Issue:436 Volume:10 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Carvajal Luis A.¹^ORCID,Neriah Daniela Ben¹,Senecal Adrien²^ORCID,Benard Lumie¹^ORCID,Thiruthuvanathan Victor¹^ORCID,Yatsenko Tatyana¹^ORCID,Narayanagari Swathi-Rao¹³^ORCID,Wheat Justin C.¹^ORCID,Todorova Tihomira I.¹^ORCID,Mitchell Kelly¹^ORCID,Kenworthy Charles²,Guerlavais Vincent⁴,Annis D. Allen⁴,Bartholdy Boris¹,Will Britta¹³⁵⁶,Anampa Jesus D.⁵^ORCID,Mantzaris Ioannis⁵,Aivado Manuel⁴,Singer Robert H.²^ORCID,Coleman Robert A.²^ORCID,Verma Amit³⁵⁶,Steidl Ulrich¹³⁵⁶^ORCID

Affiliation:

1. Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

2. Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

3. Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

4. Aileron Therapeutics, Cambridge, MA 02139, USA.

5. Division of Hemato-Oncology, Department of Medicine (Oncology), Albert Einstein College of Medicine, Bronx, NY 10461, USA.

6. Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Abstract

Dual inhibition of MDMX and MDM2 by an α-helical p53-stapled peptide (ALRN-6924) results in robust antitumor activity in acute myeloid leukemia.

Funder

National Institutes of Health

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference90 articles.